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Introduction
Metabolic bone diseases, i.e. osteoporosis and
osteomalacy, are frequent complications of patients
affected with chronic liver disease, to the point that
some authors have coined the term “hepatic osteody-
strophy” to mean the complex of structural and meta-
bolic changes of the bone in patients with both cir-
rhotic and not cirrhotic chronic liver disease(1). 
Among these, osteoporosis is particularly
important because more frequent than osteomalacy,
and often responsible of fractures, which, although
most often asymptomatic, contribute, in any case,
to morbidity and reduction of patients quality of
life.
Unlike vertebral fractures, femoral neck and
extremities ones, symptomatic by definition, are
less frequent in these patients, because, even in sub-
jects not suffering from chronic liver disease, they
occur about 10 years after the former, that is
beyond life expectancy of many patients with
chronic liver disease(2).
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SUMMARY
Osteoporosis and osteomalacy are, to date, among the
most common metabolic disease in the world.
Recently, association between metabolic bone diseases
and chronic liver diseases has been increasingly reported,
inducing many authors to create a new nosographic entity
known as “hepatic osteodystrophy”.
The importance of such a condition is, moreover, further
increased by morbidity of these two diseases, which greatly
reduce patients quality of life because of frequent fractures,
especially vertebral and femoral neck ones. For this, early iden-
tification of high-risk patients should be routinely performed
by measuring Bone Mass Density.
The explanation for the association between bone dis-
eases and chronic liver disease is still uncertain, and involves
many factors: from hypogonadism to use of corticosteroid
drugs, from genetic factors to interferon therapy. To date, few
studies have been conducted, and all with a small number of
patients, in order to establish definitive conclusions about the
possible treatment, but some evidences are beginning to
emerge about the safety and efficacy of bisphosphonates.
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RIASSUNTO
L’osteoporosi e l’osteomalacia sono, ad oggi, fra le
malattie metaboliche dell’osso più diffuse al mondo.
Di recente, l’associazione fra malattie metaboliche del-
l’osso ed epatopatie croniche si è sempre più consolidata, spin-
gendo molti autori a creare una vera e propria nuova entità
nosografica, nota come “osteodistrofia epatica”.
L’importanza di una simile condizione è, poi, ulterior-
mente accresciuta dalla morbilità di queste due malattie, che
riducono notevolmente la qualità di vita dei pazienti, per le fre-
quenti fratture, specialmente quelle vertebrali e del collo femo-
rale. Per tale motivo, la precoce identificazione dei soggetti a
più alto rischio dovrebbe essere eseguita routinariamente, tra-
mite misurazione della densità minerale ossea.
La spiegazione dell’associazione fra malattie metaboli-
che dell’osso ed epatopatie croniche è ad oggi ancora incerta,
e coinvolge molteplici fattori patogenetici: dall’ipogonadismo
all’uso dei farmaci corticosteroidi, dai fattori genetici alla
terapia con interferoni. Fino ad ora sono stati condotti pochi
studi, e tutti con un ridotto numero di pazienti, al fine di trarre
conclusioni definitive circa una possibile terapia della malat-
tia, ed alcune evidenze si sono già iniziate a registrare circa la
sicurezza e l’efficacia dell’uso dei bisfosfonati.
Parole chiave: Osteoporosi, osteomalacia, epatopatie croni-
che, bisfosfonati
Osteomalacy and chronic liver diseases
Osteomalacy is a metabolic osteopathy charac-
terized by reduced amount of bone mineral content
due to lack of mineralization. This osteopathy,
which potentially can be found in several pathologi-
cal conditions, is usually caused by reduced avail-
ability or abnormal metabolism of vitamin D(3).
Osteomalacy, although, in the past, has been report-
ed in more than 60% of patients with primary bil-
iary cirrhosis, is currently demonstrated in only a
small percentage of patients with chronic liver dis-
ease, especially in cholestatic ones(4). The changes
in prevalence of this disease, occurring in recent
decades, reflect, probably, the use of different diag-
nostic criteria, errors in selection of patients includ-
ed in trials, and nutritional improvements.
However, the gold standard for osteomalacy diag-
nosis is bone biopsy, because not all patients with
low serum levels of vitamin D suffer from this
metabolic disease(5).
As a matter of fact, vitamin D includes a
group of fat-soluble prohormones. The group
includes two compounds with very similar biologi-
cal activity: the cholecalciferol (D3), derived from
cholesterol and synthesized in animals, and the
ergocalciferol (D2), of vegetable origin. In humans,
vitamin D3 is produced by ultraviolet irradiation of
the skin from a precursor, 7-dehydrocholesterol,
which is in subcorneal layer. Adequate exposure to
sunlight grants endogenous production of cholecal-
ciferol able to satisfy the needs of whole organism,
so dietary supplement is not necessary. The diges-
tive tract absorption of vitamin D from food
sources, animal (D3) or vegetable (D2) follows
similar processes employed by other fat-soluble vit-
amins. As a matter of fact, it is incorporated into the
micelles, formed by interaction between hydrolyzed
lipids and bile, cross the intestinal epithelium, and
finally it is incorporated in chylomicrons, which, in
turn, enter the lymphatic circulation.
In various tissues, especially in the liver,
hydroxylation of cholecalciferol produce 25-
hydroxycholecalciferol (25-OHD), which then
passes into general circulation, and interacts with a
specific transport protein (vitamin D binding pro-
tein, DBP), synthesized by the liver. In the kidney,
the 25-OHD may undergo to two different hydroxy-
lation reactions, caused by different hydroxylase, 1-
hydroxylase and 24-hydroxylase, generating,
respectively, 1,25-dihydroxycholecalciferol (1,25-
OHD), the active form of D-vitamin, and 24,25-
dihydroxycholecalciferol (24,25-OHD), the inactive
form(6). As liver is involved in production of bile,
vitamin D3 absorption (fat-soluble vitamin) and
blood transport, through the DBP synthesis, and 25-
hydroxylation, which produces 25-OHD, it would
be easy to assume a high prevalence of osteomalacy
in patients suffering from chronic liver disease, not
confirmed, as mentioned above, in late years(7).
In fact, adults obtain most of their vitamin D3
from cutaneous photoconversion of 7-dehydrocho-
lesterol, and patients with cholestasis seem to have
normal skin photoconversion processes. In addition,
intestinal vitamin D3 absorption is altered only in
presence of a severe cholestasis. The succeeding
25-hepatic vitamin D3 hydroxylation has so far
been little studied in human, but in experimental
animals, with severe cholestasis, does not seem
impaired. In any case, about 2/3 of patients with
liver cirrhosis and 96% of terminal cirrhotic
patients waiting for liver transplant present with
low serum levels of vitamin D3, without, however,
demonstrated osteomalacy(8).
Osteoporosis and chronic liver diseases
Osteoporosis, as known, is defined as a value
of Bone Mineral Density (BMD), measured by
Dual-Energy X-ray absorptiometry (DEXA), less
than 2.5 standard deviations below the average of a
young adult population control bone mass peak
(corresponding to the normal bone mass peak) (T
score -2.5). Although the risk of fractures increases
gradually with BMD decreasing, other clinical risk
factors for fractures have been identified, all inde-
pendent from BMD, such as advanced age,
menopause, Body Mass Index (BMI) <19 kg/m2
(expression of malnutrition or poor nutrition), alco-
hol intake >3 units/day (1 unit = 8g alcohol), an
oral corticosteroid therapy >5 mg/day for at least 3
months, previous fragility fractures, and a maternal
history of hip fracture. Most important of these
independent risk factors is represented by previous
fragility fractures. Once a vertebral fracture
occurred, the risk of further vertebral fracture
increased by 10 times, while risk of a subsequent
hip fracture increase of 2.3 times(9).
In patients affected with chronic liver disease
it’s possible to find out many of these risk factors,
including hypogonadism, malnutrition, excessive
alcohol intake and use corticosteroid drugs (e.g.
treatment of autoimmune liver diseases, as primary
biliary cirrhosis and primary sclerosing cholangi-
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tis), and, in addition, many patients with primary
biliary cirrhosis are, by definition, postmenopausal
women. Contrariwise, it is still questionable if liver
cirrhosis and cholestasis are, themselves, indepen-
dent risk factors for osteoporosis, since this topic
has been yet no completely studied(10).
As testosterone is metabolized to estrogen,
long duration hypogonadism, in men, is associated
with a reduction of circulating estrogens and conse-
quent reduced bone turnover, with decreased
osteosinthesis, nevertheless reversible, with ade-
quate hormone replacement therapy.
Hypogonadism, measured via free serum
testosterone levels dosage, was described in almost
3/4 of patients with cirrhosis awaiting liver trans-
plant, but did not appear related to the aetiology of
cirrhosis (see below)(11). Excessive alcohol intake, as
well, is an independent risk factor for osteoporosis.
Alcohol intake seems to inversely correlate with
BMD. Alcoholism, a characteristic of many patients
with chronic liver disease, in turn, is associated
with reduced testosterone serum levels, which may
contribute, by hypogonadism, to determine osteo-
porosis in these patients, and with low vitamin D3
serum levels(12).
The role of hypogonadism in liver cirrhosis
Among osteodystrophy pathogenic mecha-
nisms in chronic liver disease, a particularly impor-
tant role has certainly hypogonadism. Absolute tes-
tosterone low levels and estrogens relative increase
point out hypogonadism in men with liver cirrhosis.
Advanced liver disease is characterized by this ano-
maly, as evidenced by a study that showed levels of
circulating free testosterone lower in men with liver
cirrhosis, than in non-cirrhotic controls (0.11+0.02
vs. 0.22+0.03 nmol/L)(13).
Frequency with which low free testosterone
levels is observed appears to be extremely high, up
to 100% of patients studied(14). Reduction of testos-
terone levels depends on a lower gonadal produc-
tion, which is dependent, at least in part, by altera-
tion of sensitivity of the hypothalamic-pituitary-
gonadal axis. Several other factors contribute to
abnormalities of estrogens/testosterone ratio in cirr-
hotic patients. Among them, alteration of testostero-
ne production circadian rhythm(15) and reduced
hepatic uptake of sex hormones, which normally
“covers” 20-50% of their physiological clearance.
Finally, a role is played by alteration of hypothala-
mic regulation: as a matter of fact, patients affected
with liver cirrhosis show LH and FSH levels only
slightly increased, but certainly not high as expect
because of severe lack of circulating sex hormo-
nes(16). Since endocrine alterations described above
play heavy clinical role in male, it is clear that most
of studies on this aspect have been conducted in
cirrhotic males. However, limited data, obtained in
female patients with cirrhosis, show that levels of
testosterone, LH and FSH were significantly redu-
ced(17). In young women with liver cirrhosis, these
hormonal changes can lead to secondary amenorr-
hea(18), emphasizing the link between osteoporosis
and liver disease.
Measurement of BMD in patients with chronic
liver disease: who and when?
Despite some differences, most of guidelines
and recommendations agree about timing of DEXA
determinations in chronic liver disease patients: in
every menopause patient or, if male, in subject with
more than 50 years of age, and/or if suffering from
hypogonadism, and/or if treated with corticoste-
roids for long term period, and/or if reports history
of fragility fractures. In all these cases, if an osteo-
porosis framework is diagnosed, a medical treat-
ment should be immediately started(19,20).
BMD should be measured in patients with
liver cirrhosis too, both in biliary and in non-biliary
one, before hepatic transplant. Indications to BMD
measurement are less clear in patients with choles-
tatic liver disease, not waiting for transplant. For
example, the guidelines of the American
Gastroenterological Association suggests that BMD
should be measured in all patients with primary
biliary cirrhosis at diagnosis time, while others
recommendations suggests BMD measurement
only in cholestatic patients with bilirubin greater
than 3 times the upper limit of normal range(19,20).
Frequency of BMD measurements is still
debated. In absence of osteoporosis, but in presence
of risk factors for the disease, there is probably no
need to repeat BMD measurement more often than
once every 2-3 years. Contrariwise, patients who
received or receive high corticosteroids doses might
be re-evaluated once a year. Considering, then, that
osteoporosis may also be first clinical manifesta-
tions of an underlying cholestatic liver disease, it is
advisable to screen for anti-mitochondrial antibo-
dies all osteoporotic patients with low BMD and
high cholestasis markers (gamma-glytamyl trans-
peptidase, γ-GT and alkaline phosphatase).
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Finally, it seems there are no indication to rou-
tine measurements of serum and urinary markers of
bone turnover neither to stratify fractures risk, nor
to assess deterioration of bone health during follow-
up(19,20).
Pathophysiology of osteoporosis in chronic liver
diseases
As above mentioned, sex hormone changes
probably account for a mainly role in pathophysio-
logy of osteoporosis in cirrhosis. In general, howe-
ver, biological mechanisms underlying osteoporosis
of patients with chronic liver diseases are complex
and nowadays slightly understood, and include,
perhaps, also genetic and acquired factors. Among
the former, it must be consider collagen 1α1, vita-
min D receptor, estrogen receptor and LRP5 (low
density lipoprotein receptor-binding protein 5)
genes, but their polymorphism has not yet been
associated with an increased, specific, fractures
risk, even in patients without chronic liver disea-
se(21). Bone loss, subsequent to bone mass peak
overtaking, can be explained looking at a possible,
acquired, dissociation between bone formation and
resorption. Increase in osteoclasts activity, resulting
in enhanced bone resorption, is mediated by osteo-
clastogenic pro-inflammatory cytokine, such as IL-
1 and TNF, often involved both in hepatic inflam-
mation and fibrosis.
Lately, receptor activator of NF-kβ (RANK)
protein and RANK ligand (RANKL), in addition to
osteoprotegerin (OPG), have been involved in
osteoclastic bone resorption mechanisms in patients
with no hepatic osteoporosis, while assessment of
their involvement, in chronic liver disease patients,
has, so far, produced contradictory results(22).
Contrariwise, reduction of bone formation,
observed in patients with chronic liver disease, was
associated with low serum levels of insulin-like
growth factor-1 (IGF-1), a protein known to be
involved in bone remodelling and maintenance of
bone mass(23).
A clear association between IGF-1 serum
levels and osteoporosis, in chronic liver disease in
human, has not been, however, still clearly demons-
trated(24). Vitamin K is also involved in bone metabo-
lism, by carboxylation of glutamic acid residues of
bone proteins, such as osteocalcin, but there are,
still, no literature data about vitamin K deficiency
role in osteoporosis pathogenesis in hepatic disea-
ses(25).
Finally, although indirect (unconjugated) bili-
rubin inhibits the activity of osteoblasts and their
function, both in vitro and in animal models, in
vivo studies, conducted in patients with chronic
liver disease, showed no correlation between total,
direct and indirect bilirubin levels and BMD(26).
Prevalence of osteoporosis in chronic liver diseases
Cirrhosis
Several studies conducted over the past two
decades demonstrated that prevalence of osteoporo-
sis in patients with liver cirrhosis, albeit with wide
variability among the studies, is around 33%. These
differences in prevalence reflect, probably, differen-
ces in age, etiology and severity of liver disease,
nutritional status (expressed as BMI), and in hypo-
gonadism status of studied patients. In all cases,
liver cirrhosis seems to increase the risk of fractures
by about 2 times(27).
Biliary Diseases
The etiologic relationship between primary
biliary cirrhosis and osteoporosis have been, espe-
cially in the past, very controversial, because
patients suffering from this disease are classically
menopausal women, themselves, therefore, at high
risk of osteoporosis. However, more recent studies
confirmed a substantially increased osteoporosis
and fractures risk in this particular group of patients
compared with age-matched healthy controls, with
a prevalence of 43% for osteoporosis and 22% for
fractures(28).
In primary sclerosing cholangitis prevalence
of osteoporosis stands at 20.3%, with wide variabi-
lity among the studies, while risk of fracture, appro-
ximately 15%, correlates with increasing age, more
advanced biliary disease and duration of a coexis-
ting and associated inflammatory bowel disease(29).
Other liver chronic diseases 
There are some reports of increased prevalen-
ce of osteoporosis and fractures in patients with no
cirrhosis or biliary liver chronic diseases, such as
chronic hepatitis, and those undergoing liver trans-
plant.
Viral hepatitis
In a recent study, BMD was low in patients
with chronic non-cirrhotic h¬epatopathy, suffering
from chronic viral infection by hepatitis C virus.
The study, however, did not describe any control
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group and there were no details about alcoholic
intake of patients(30).
A possible negative effect of ribavirin and
interferon therapy, used in the treatment of patients
with HCV-related chronic active hepatitis, on BMD
of these subjects, initially showed in some studies,
it was not lately confirmed. Interferon reduces mar-
kers of bone turnover and appears to inhibit forma-
tion of osteoblasts, while ribavirin osteoporizing
mechanisms are totally unknown(31).
Liver transplant
Patients who underwent liver transplant, sho-
wed post-transplant high prevalence of osteoporosis
and fractures. As long-time survival of these
patients is known to be considerably increased in
recent years, osteoporosis has become a major
cause of their co-morbidity(32). Etiology of this
metabolic disorder is multifactorial, and risk factors
contributing to it are both pre-transplant and post-
transplant ones. Among pre-transplant risk factors,
pre-transplant fragility fracture is more predictive
for post-transplant recurrent fractures compared to
the simple values of BMD. However, BMD measu-
rement, of course, is also crucial in these patients,
cause low BMD values, before and after transplant,
was, however, associated with a higher frequency
of fractures. Furthermore, there is large consensus
about effects of age (>45 for women, >65 for men),
gender (female, although some studies showed an
increased susceptibility to osteoporosis and fractu-
res of male patients), menopausal status (postmeno-
pausal), type of pre-transplant liver disease (increa-
sed risk for alcohol-related and/or cholestatic disor-
ders?), and exposure to corticosteroids in the pre-
transplant phase, on osteoporosis and fractures risk
in post-transplant patients. Other pre-transplant fac-
tors, for which there is no unanimous consensus, in
regard themselves as risk factors for post-transplant
osteoporosis and fractures, are 25-OHD, PTH
serum levels, bone turnover markers, and biochemi-
cal parameters of liver function (with reference also
to the Child-Pugh class of membership, with class
C at greater risk of osteoporosis than class A) and
kidney(33,34).
Among post-transplant factors, however, the
most important is represented by acute osteopenia
that occurs immediately after transplant, with a sig-
nificant decrease of BMD in the first 3 months, and
a return to pre-transplant values only after about 2
years. Therefore, it was reported a frequency of fra-
gility fractures, from minor trauma or apparently
non-traumatic ones, both vertebral, symptomatic or
not, and non-vertebral, femoral and/or of extremi-
ties, of about 21%, most of which within first 2
years after transplant.
Unlike pre-transplant fracture, most of post-
transplant ones seem to be symptomatic, and, most
commonly, vertebral ones, followed by rib ones,
with a minor prevalence of hip and extremities
ones, probably because predominantly cortical bone
sites are, in fact, less susceptible to osteoporotic
fractures compared with trabecular ones(35,36). Use of
high doses of corticosteroids and other immunosup-
pressive agents, such as cyclosporine A and tacroli-
mus, immobility and poor nutrition, probably, all
contribute to cause rapid bone loss of immediate
post-operative period of these patients(36).
Cumulative steroid doses, administered in
early post-transplant, and, in this delicate phase, at
particularly high dosage, has been repeatedly impli-
cated in pathogenesis of acute bone loss observed
in these patients, while current use of lower steroids
doses after transplant, as shorter time of hospitali-
zation and immobilization, explain, probably, the
sharp reduction of osteoporosis and fractures fre-
quency in post-transplant observed in the last deca-
de and reported in several studies(37).
In contrast, effects of calcineurin inhibitors
(e.g. tacrolimus), administered after liver transplant
as anti-rejection drugs, on bone turnover are still
controversy, as it is difficult to separate possible
bone loss effects of these drugs than those of corti-
costeroids drugs, associated, generally, in anti-
rejection treatment regimens. However, it seems
that patients treated with tacrolimus had an earlier
recovery of mineral content and trabecular bone
structure compared to patients taking cyclosporine
A, but effects of both on bone loss in early post-
transplant remain unclear. Both, however, seem to
increase turnover and bone resorption, cyclospori-
ne, perhaps, more than tacrolimus(38). However,
post-transplant variables that do not seem to have
any effect on prevalence of fractures after interven-
tion are: waiting time before the procedure, hospita-
lization length, immunosuppressive doses used,
both daily and cumulative, and episodes of organ
rejection(39).
Treatment of osteoporosis in chronic liver
diseases
Current recommendations suggest starting
osteoporosis treatment in all patients affected with
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liver chronic disease, especially if aged >65 years,
and/or if 7.5 mg or more of steroid drugs are requi-
red daily for more than three months, although it is
probable an increased osteoporotic risk for lower
steroid doses too. In younger patients, suffering
from chronic liver disease, treatment is indicated if
BMD shows T-score values of -2.5(19,20).
Although serum and urine markers of bone
turnover have been used in the assessment and
treatment monitoring of patients affected with pos-
tmenopausal osteoporosis, there are few studies
about their use in osteoporotic patients with chronic
liver diseases, and, actually, they should not be rou-
tinely indicated in this patients subgroup(40).
Treatment of osteoporosis in patients with chronic
liver diseases is based, essentially, on results of
large trials conducted in women with postmenopau-
sal osteoporosis.
Contrariwise, there are, to date, only few,
small studies specifically conducted in patients with
chronic liver diseases, particularly affected with
primary biliary cirrhosis, that, moreover, conside-
red, as primary outcome, the BMD increase rather
than frequency reduction of fragility fractures(41).
Vitamin D and calcium
Vitamin D and calcium supplementation has
been shown to be efficient in reducing fractures in
elderly patients housed in protected residences.
Consequently, all patients included in evaluation
trials of other kinds of treatment of osteoporosis are
regularly treated with vitamin D and calcium too,
usually 400-800IU of vitamin D and 1000-1200mg
of elemental calcium per day. However, there are
very few studies on effectiveness of supplementa-
tion with vitamin D and calcium and their optimal
dose and formulation in patients with chronic liver
diseases but, in any case, vitamin D deficiency
should be corrected to obtain a 25-OHD serum
values of at least 25-30 ng/mL. In patients with
documented associated malabsorption, will be used
vitamin D higher doses (42).
Bisphosphonates
Bisphosphonates (alendronate, etidronate,
ibandronate, and risidronate), drugs acting via inhi-
bition of bone resorption, were all used in treatment
of post-menopausal osteoporosis, most often in
combination with vitamin D and calcium(43). There
are, however, very few studies about their use in
patients with cirrhosis, especially with primary
biliary cirrhosis, and, due to this reason, data about
their safety and effectiveness are still inadequate. In
patients with primary biliary cirrhosis, alendronate,
more than etidronate, seems to increase bone mass
and BMD and improve markers of bone turnover,
while it seems to show no reduction in fractures
incidence(44). Complications from esophageal daily
administration of alendronate were never observed,
although other studies, also conducted in patients
with primary biliary cirrhosis, suggest that alendro-
nate is better tolerated when administered once a
week, rather than daily(45). In patients affected with
non-biliary cirrhosis, bisphosphonates seem, ove-
rall, well tolerated in weekly administration, alt-
hough they must be used with care in patients with
a recent history of bleeding and/or with esophageal
sclerotherapy, but these studies were carried out on
too small series to make judgments about their
effectiveness in this different context(46).
Bisphosphonates have also been used in some
small studies in patients undergoing liver trans-
plant, to reduce incidence of fractures after surgery.
Most of them used intravenous pamidronate, obtai-
ning variable results, from a fractures reduction to a
BMD rising without change in the incidence of
fractures, to neither fracture reduction nor BMD
rising. Failure in detection of protective effect of
this drug against fracture, found in some of these
studies, may reflect, however, only the size of eva-
luated sample, whereas overall decrease of fractures
was observed in post-transplant during the last 20
years(10). In this context, it is important to take care
of a particular side effect of bisphosphonate thera-
py, which is osteonecrosis of the jaw. Most of
reported cases involved oncologic patients treated
with intravenous pamidronate or zoledronic acid,
but it has been reported even in patients without
cancer in oral treatment. About 2/3 of cases occur-
red after tooth extraction. It is not absolutely known
relevance and prevalence of this adverse reaction in
patients with chronic liver disease(47).
Other treatments
Hormone replacement therapy
Hormone replacement therapy (HRT) is
actually a second-line choice therapy for osteoporo-
sis treatment, due to evidence of an increased risk
of thromboembolic and gynecologic malignant neo-
plasm. However, it may be administered with safety
in patients with chronic liver diseases, especially in
pre-menopausal women with documented hypogo-
nadism or in early menopause (before 45 years),
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usually transdermal in order to increase BMD (48).
Therefore, there are only few little studies about the
effect of HRT on osteoporosis, especially due to
uneasy recruiting of women in trials of this kind,
highlighted, also, by high drop-out rate from treat-
ment, and it was not, then, possible to select a suffi-
ciently high number of patients to evidence a positi-
ve effect of treatment on osteoporosis, including
fractures(49).
Raloxifene
Raloxifene is an estrogen receptor modulator,
which has been shown to reduce frequency of ver-
tebral fractures in women with postmenopausal
osteoporosis. Contrariwise, it does not seem to
affect the frequency of femoral fractures. Currently,
there are few data on its safety and efficacy in
osteoporotic patients with chronic liver diseases(50).
Testosterone
Hypogonadic male patients suffering from
chronic liver diseases may be treated with transder-
mal testosterone, as treatment normalizes hormone
values, without rapid increase of its serum levels, as
caused, instead, after oral or controlled release
administration. Currently, there are few data about
its safety and efficacy in osteoporotic patients affec-
ted with chronic liver diseases. By the way, a limit
to this kind of treatment it could be the increased
risk to develop an hepatocellular carcinoma.
Strontium ranelate
Strontium ranelate is a reducing non-vertebral
and vertebral fractures drug successfully used in
patients with post-menopausal osteoporosis. Its
mechanism of action is not well-known, and, to
date, there are no studies on its efficacy and safety
in patients with chronic liver disease, especially in
intolerant to bisphosphonates ones(52).
Recombinant PTH
Recombinant PTH was used for secondary
prevention of fragility fractures in women with
post-menopausal osteoporosis, intolerant to bis-
phosphonate. It works rising bone synthesis. To
date, there are no studies on its safety and efficacy
in patients with chronic liver diseases(53).
Conclusions
Osteoporosis is the most important form of
liver osteodystrophy, often clinically evident and,
therefore, underdiagnosed. Despite a decline of
osteoporosis incidence in last 20 years in patients
with end stage chronic liver disease, a large rate of
patients waiting for liver transplant is affected with
osteoporosis, and many of them have already had
fractures. It is important to identify these indivi-
duals, cause pre-transplant fractures increase risk of
post-transplant ones, while fracture, whenever
occurred, are associated to a great morbidity, even
in non-transplanted cirrhotic patients. Identification
of patients with chronic liver disease at high risk of
osteoporosis and fractures contemplate BMD mea-
surement, although it should be carefully conside-
red other clinical risk factors. Evidence of benefi-
cial effect of osteoporosis treatment in these parti-
cular patients, however, is still, mainly, based on
extensive studies conducted in women with pos-
tmenopausal osteoporosis, being, to date, just few
and with no appropriate number of subjects studies
on patients with chronic liver diseases.
In particular, bisphosphonates appear to
improve BMD and to be well tolerated, but studies
in this regard are too small to show a real beneficial
effect, even on the fractures frequency.
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